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Abstract: In this study, we analyze the determinants of biomedical scientists’ 
participation in various types of activities and outputs related to medical innovation. 
More specifically, we argue that scientists occupying brokerage positions among their 
contacts will in a more favorable position to deliver medical innovation outcomes, 
compared to scientists embedded in more dense networks. However, we also theorize 
that beyond a threshold, the coordination costs of brokerage may surpass its potential 
benefits. In addition to that, we study the influence of two individual-level attributes as 
potential determinants of the participation in medical innovation activities: cognitive 
breadth and perceived beneficiary impact. We situate our analysis within the context of 
the Spanish biomedical research framework, where we analyze a sample of 1,292 
biomedical scientists. 
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1 Introduction	and	research	context	
An increasing amount of research in the fields of sociology and management has 
centered on whether and how the position of actors in a social network influences their 
creativity and innovation (Baer, 2010; Burt, 2004; Obstfeld, 2005; Wu, Chang, & Chen, 
2008). These studies have provided robust evidence about the existence of a strong 
relationship between network structure and innovation performance. However, the 
question about the particular characteristics of network structures that are most conducive 
to innovation remains an open debate. This issue is of particular importance in the 
context of biomedical research, where initiatives to foster translational research and 
cooperation between biomedical communities have become central ingredients of the 
policy agenda to foster medical innovation. 
The question of how to accelerate the diffusion of research findings into clinical 
practice has become an important issue among academics, practitioners and public policy 
actors. The concern stems from the fact that few of the most promising biomedical 
discoveries effectively result in direct and tangible impacts on human health 
(Contopoulos-Ioannidis, Ntzani, & Ioannidis, 2003). For instance, the length of time 
from a basic discovery to approval of a new drug averages around 13 years and the 
failure rate exceeds 95% (Collins, 2011); or as pointed out by Wheling (2010), from 
1991 to 2000 only 11% of drugs delivered to humans for the first time were successfully 
registered, with success rates varying dramatically among therapeutic areas. 
Additionally, this literature has highlighted the difficult transit from basic scientific 
findings to different types of medical innovation, such as drug development or new 
medical treatments. 
In order to increase the health benefits of investing in biomedical science, a 
discussion around the concept of translational research has consistently proliferated 
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among leading scholars from the biomedical research community (Duyk, 2003; F. 
Marincola, 2003; E. A. Zerhouni, 2007). There is substantial agreement on the idea that 
the essential objectives of translational research should involve interventions to improve 
human health through the rapid progression of basic scientific knowledge to patient 
benefit. The rhetoric and terminology of translational research has permeated the policy 
agenda of the majority of public and private funding agencies worldwide. For instance 
the US National Institute of Health (NIH) made translational research a strategic priority 
by releasing in 2003 the Roadmap for Clinical Research (Zerhouni, 2003). In Europe, 
initiatives in this direction have been also presented (European Science Foundation, 
2012).  
Even though “translational research means different things to different people” 
(Woolf, 2008, p. 471), and the past few years have witnessed a flourish of theoretical 
models adopting a terminology to conceptualize the different steps through which 
biomedical knowledge moves forward from the “bench to the bedside”, there are some 
common foundations about what is generally understood by translational research that 
provide the grounds for the following working definition. Translational research refers to 
a mode of research based on the dialogue and cooperation among multiple actors - basic 
scientists, clinical scientists, medical practitioners, patients, among others – that elicits a 
bi-directional flow of knowledge with the objective to improve healthcare. This two-way 
flow of knowledge involves feeding basic scientists with questions for research based on 
clinical practice, and facilitating the transfer of new theories of disease pathways into 
clinical practice (Marincola, 2003; Rey-Rocha & Martín-Sempere, 2012).  
In this paper we propose two contentions. First, the critical role played by “brokers” 
or “connectors” as a particularly salient issue in the translational research model. As 
pointed out by Hobin et al. (2012), a successful translational research environment 
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demands a structure that promotes interaction between different people trained across 
different disciplines and working in different contexts. For instance, an effective 
communication between those who are specialized in fundamental biology and those who 
have experience in clinical methods becomes essential to move knowledge forward 
through the translational research pipeline. However, moving and spreading new 
knowledge in the biomedical context is particularly challenging since it involves an 
effective communication and interaction between many different professional groups. 
Evidence suggests the presence of strong social boundaries between each of the multiple 
professional communities involved in biomedical research and healthcare (Ferlie, 
Fitzgerald, Wood, & Hawkins, 2005; Gittelman, 2013). These distinct communities are 
reflected in different professional roles, identities and traditional work practices. 
Therefore, a major challenge for translational research is to bring together contrasting 
scientific paradigms based on the basic and applied logics of biomedical research. Our 
first contention is that those researchers who are capable to liaise and coordinate a 
diverse range of actors contributing to the biomedical research process, should be more 
likely to develop new medical technologies and innovations in healthcare.  
Second, in addition to the structure of their personal research networks, the scientists’ 
involvement in medical innovations is likely to be a function of certain individual-level 
attributes. Participation in translational research activities and outputs are a good 
expression of the scientists’ capacity to identify clinical needs (Hobin et al., 2012) and to 
successfully exploit routes to move fundamental knowledge into clinical applications. 
This implies an explicit focus on the micro-level, individual abilities and motivations of 
scientists towards research. More specifically we contend that the scientists’ 
heterogeneity in terms of their cognitive breadth and their perceived impact on 
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beneficiaries may explain differences in the scientists’ likelihood to develop medical 
technologies and be involved in innovations associated to the delivery of healthcare.  
Extant literature of innovation in the biomedical context has taken explicit account of 
the critical importance of knowledge brokers to overcome collaboration barriers and 
bridge translational gaps (Currie & White, 2012; Lomas, 2007). However, research has 
not addressed empirically so far the question of which is the most effective structural 
pattern of collaborations at the micro-level to facilitate biomedical scientists’ 
identification and exploitation of potential opportunities for innovation. We propose to 
look at this process through a social capital perspective since biomedical scientists can 
widely differ in their personal network structures and content. We expect different types 
of personal networks to be linked to the degree of involvement in medical innovation 
outputs. As a way to explore this relationship, we account for different types forms of 
ego-network structures drawing insights from social capital and social network 
literatures. Our ultimate goal is to go one step further in the understanding of the role of 
interactions and knowledge flows between biomedical actors as enablers of medical 
innovation. 
The paper is structured as follows. In the following section, we begin by discussing the 
importance of considering the ego-centric structural position as an antecedent for the 
scientists’ engagement in medical innovation. Afterwards, we acknowledge the relevance 
of cognitive skills and perceived impact of beneficiaries as potential antecedents of 
translational research. Then, we contextualize our research and present the results. The 
last section ends by discussing the main theoretical and empirical findings from our 
study. 
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2 Theory	and	hypothesis	
2.1 Network	brokerage	and	medical	innovation	
 
A significant body of literature from multiple fields has explored how the position 
occupied by individuals in a social network can influence creativity and other 
performance-related outputs. A social network can be defined as a set of actors and the 
relations that connect the actors (Kilduff & Tsai, 2003). An ego-centric approach to 
social networks defines the structure of each individual network in terms of lack of 
connectivity between the contacts in the network. Research from the fields of 
management and innovation have used ego-centric social network approaches to 
evidence that certain network positions partly explains a range of individual-level 
outcomes such as job performance (Sparrowe, Liden, Wayne, & Kraimer, 2001), 
innovation (Obstfeld, 2005; Wu, Chang, & Chen, 2008) or creativity in organizations 
(Baer, 2010; Burt, 2004; Perry-Smith, 2006). Scholars studying the processes explaining 
the creation of knowledge have also emphasized the role of particular network structures 
in facilitating knowledge creation (McFadyen & Cannella, 2004; McFadyen, Semadeni, 
& Cannella, 2009).   
Although research has demonstrated the importance of the structural position in 
the network for innovative-related outputs, there is less agreement on the underlying 
mechanism through which this structural advantage is gained. In this sense, research 
dealing with structural relationships and their impact indicates that two opposite network 
structures - structural holes and dense networks - both bear a potential to generate 
positive effects on innovation. These effects, however, operate through differentiated 
mechanisms in each case. On the one side, Burt (1995) suggested that the greater benefits 
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from a structural position are obtained through spanning structural holes. When a focal 
individual (ego) is connected to two individuals (alters) that are not connected between 
themselves, a structural hole exists. In the research network literature, an individual 
holding this network position is known as a ‘broker’ (Burt, 1995; Fernandez & Gould, 
1994). Positive returns to brokerage positions are well documented (e.g.: Cross & 
Cummings, 2004; Lee, 2010; Soda, Usai, & Zaheer, 2004), and are commonly attributed 
to a privileged access to novel information and a greater control over its use. Having an 
egocentric network rich in structural holes provides access to more diverse, potentially 
novel information (Burt, 2004; Zhou, Shin, Brass, Choi, & Zhang, 2009). The underlying 
rationale is that alters that are not connected among themselves belong to different social 
and/or professional circles. This brokerage position enables the focal individual to gain 
access to heterogeneous perspectives and non-redundant knowledge. There is also a 
control advantage derived from occupying a brokerage position. Since actors in a 
brokerage position provide the only connection between two other actors, any flow of 
information or knowledge between these two actors necessarily passes through the broker 
(Burt, 1995; Lee, 2010). Controlling the flow of information between disconnected 
others may allow the focal actor to determine how this information will be used and 
which actors will be included or excluded in a brokered exchange (Rider, 2009).  
On the other side, it has been argued that cohesive network structures, in which 
actors are densely linked to each other, are desirable for a number of reasons. First, 
networks formed by closely tied actors facilitate the emergence of mutual trust, common 
norms and a collective sense of reciprocity that, in turn, smooth the flow of knowledge 
among the members in the network and favor the creation of novel knowledge (Coleman, 
1994). Because actors in dense networks are more able to rely on norms and sanctions 
against opportunism (Zaheer & Bell, 2005), misbehavior is less likely to arise and 
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coordination costs in the network are reduced. Dense networks can also increase actors’ 
engagement in putting into practice the potential knowledge accessed through the 
network because it is easier to gain the cooperation of network members towards a 
common interest (Obstfeld, 2005; Phelps, Heidl, & Wadhwa, 2012). Some scholars have 
found that network density increases knowledge sharing and knowledge creation among 
network contacts (Morrison, 2002; Reagans & McEvily, 2003). Dense networks also 
appear to have positive influences on creativity. For instance, Amabile, Barsade, Mueller, 
& Staw (2005) suggest that closed networks promote positive affect between the network 
members, and this predicts higher levels of creative-related outcomes. From an ego-
network perspective, dense networks are characterized by the existence of close triads 
between ego-networks’ direct contacts. When two ego’s contacts share a tie between 
them, a closed triad exists. Hence, dense ego-networks are measured as the existence of 
closed triads between ego and alters (Burt, 2004).  
The theoretical discussion raised above has important implications for modeling 
the impact of specific ego-network structures on the participation of biomedical scientists 
in activities and outputs related to medical innovation. We expect that ego-networks rich 
in structural holes are particularly important predictors of the scientists’ engagement in 
medical innovation. The rationale for this claim is that actors with the capacity to mediate 
between disparate communities may be in a more advantageous position to identify, 
locate and mobilize the resources and capabilities needed to get involved in medical 
innovation.  
Holding an ego-network rich in structural holes reflect a mediating role between 
actors located in disparate communities. That means that the range of knowledge and 
resources available for the focal scientist will be comparatively higher compared to 
scientists embedded in dense networks (Rotolo & Messeni, Petruzzelli, 2012), who will 
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tend to rely on more homogeneous knowledge. Linkages to weakly connected actors 
means a greater exposure to different approaches, outlooks and interests, allowing the 
focal scientist to frame their research problems from a broader perspective and to align 
these problems to the reality of human disease and the needs of health care professionals 
from different social groups. Thus, keeping a sparse collaborative network makes 
additional cognitive material available for the focal scientist, increasing the recombining 
knowledge possibilities and the subsequent materialization in the development of novel 
therapeutic solutions. 
We expect, however, that our predicted relationship between ego-network 
brokerage and the degree of participation in medical innovation is not lineal. Empirical 
evidence on ego-network research shows, for instance, that the benefits of weak ties for 
creativity-related outcomes is limited, and that there is an optimal level, rather than a 
maximum level, of weak ties where outcomes are maximized (Baer, 2010; A. McFadyen 
& Cannella, 2004; Zhou et al., 2009). Similar effects may be expected for the case of 
biomedical scientists occupying brokerage positions. Spanning structural holes entails 
costs for the broker in terms of time, energy and cognitive resources needed to cultivate 
and maintain these ties. Disconnected alters tend to belong to different social and 
professional circles (Burt, 1995) and be dissimilar among them in terms of cognitive 
frames and norms of conduct. Hence, the necessary egos’ cognitive efforts to 
simultaneously communicate with alters may be higher compared to scientists embedded 
in more dense networks. Further, ego’s capability to process and benefit from the 
diversity of knowledge and resources coming from the network is limited (Cyert & 
March, 1963; Ocasio, 1997; Simon, 1955). When the diversity of information accessible 
through the network is too large, individuals may experience information overload, 
which makes more difficult to make sense of it (Weick, Sutcliffe, & Obstfeld, 2005; 
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Zhou et al., 2009) and therefore use it to identify and exploit opportunities for medical 
innovation.  
While the current debate on translational research has provided insights into the 
critical role of brokers for the mobilization of basic knowledge into medical innovation, 
this literature has not empirically assessed this relationship. Furthermore, the potential 
costs of brokerage positions have not been considered, thus implicitly assuming positive, 
linear relations between brokerage positions and medical innovation outcomes. However, 
costs associated to brokerage positions are likely to operate in our context of analysis. 
For instance, basic scientists spanning structural holes between clinical researchers and 
patients’ representatives need to be responsive to the distinct interests of both 
communities (Ferlie, Fitzgerald, Wood, & Hawkins, 2005). This requires the investment 
of a significant amount of cognitive resources and attention to achieve the innovation 
performance benefits associated to brokerage positions. Lacking common ground may 
limit the potential benefits from this structural position.  
Thus, we can expect that an adequate balance between the benefits and the costs 
of brokerage will be obtained at intermediate levels of ego-network brokerage and 
therefore, the participation in medical innovation activities will be higher at that point.   
Hypothesis 1: Ego-network brokerage will have an inverted u-shaped relationship 
with scientists’ degree of participation in medical innovation activities, which will 
be maximized at intermediate levels of brokerage. 
2.2 Individual	determinants	of	biomedical	 scientists’	participation	
in	medical	innovation	
Some prior work on translational research has focused on the individual factors 
that are particularly critical for the adoption of translational-research practices among 
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biomedical scientists. For instance, research has noted that it is important to count with 
an interdisciplinary educational background (Feldman, 2008; Rubio et al., 2010). 
Research also suggests that there is a significant motivational factor behind the scientists’ 
engagement in medical innovation activities. The desire to “make a difference” by 
ultimately improving human health may fuel the scientists’ interests in searching for 
effective ways to make a positive impact. Testing basic models into clinical reality, for 
instance, may be viewed as a way to channel this interest (Hobin et al., 2012). These 
ideas led us to question the relevance of two blocks of individual-level features 
potentially related to the scientists’ engagement in various forms of medical innovation.  
Breadth of cognitive skills. An important challenge to bridge the gap between 
basic research and clinical practice is directly related to the biomedical scientists’ skills 
and academic background. In the past, basic biomedical scientists were only assumed to 
develop research skills aimed to make their mark and gain reputation in their scientific 
field. However, the adoption of a translational research logic to the organization of 
medical research suggests that an adequate combination of basic and clinical skills is 
essential to maximize the scientists’ participation in medical innovation activities. For 
instance, Hobin et al. (2012) indicate that there are three skills that biomedical scientists 
must learn to succeed when engaging in research projects with an explicit translational 
component. The first one is the ability to define a health need with the same precision as 
a basic science hypothesis. The second is about understanding how to develop 
inexpensive and robust assays applicable to humans. And the third skill is related to the 
conceptualization of a pathway to regulatory approval or clinical adoption. Although 
some specific training programs are increasingly covering these issues, basic research 
programs are normally focused on the specialization of one (or few) research topics. It is 
well documented that narrowly defined training trajectories represent a barrier that 
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complicates a smooth translation of basic knowledge into clinical practice (Cochrane 
et al, 2007). Other scholars have suggested that to cross the gap from lab bench to patient 
bedside, biomedical scientists should receive specific training in research methodology 
including clinical trial design and medical statistics (Homer-Vanniasinkam & Tsui, 2012; 
Kurpinski, Johnson, Kumar, Desai, & Li, 2014). Similar arguments apply for biomedical 
scientists performing biomedical research at the clinical side of the translational research 
continuum. It is increasingly acknowledged that clinical research and clinical practice 
should be fully based on empirical evidence (Ioannidis, 2004). This means that clinical 
scientists should be able to prioritize, for instance, those biological problems with a 
greater potential impact for clinical practice. Or they should be able to recognize when 
sufficient evidence has been accumulated for an intervention to be translated into a 
clinical guideline or a new treatment (Kelley et al., 2012; Ferlie et al., 2005). However, 
most training programs in biomedicine are still grounded on a strict separation between 
academia and health care (Borstein et al, 2011), which perpetuates the existing silos 
between theory and practice. 
Taken together, the above arguments support the prediction that those scientists who 
have acquired a broader set of basic and clinical skills will be more capable to bridge the 
gap between basic research and clinical practice,  and as a consequence they will be more 
susceptible to engage in a broader range of medical innovation activities, compared to 
peers with a narrower set of basic and clinical skills. This gives rise to the following 
hypothesis: 
Hypothesis 2: Breadth of cognitive skills will have a positive relationship with 
the scientists’ degree of participation in medical innovation activities. 
Perceived impact on beneficiaries. Social psychology scholars have 
conceptualized perceived impact on beneficiaries as the degree to which individuals are 
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aware that their own actions have the potential to improve the welfare of others (Grant, 
2008; Grant, 2007). Individuals reporting higher levels of perceived impact on 
beneficiaries are particularly conscious about the direct connection between their 
behavior and the outcome they can exert in other people or groups. It has been 
documented that the higher the perceived impact on beneficiaries, the greater the 
individual’s engagement in actions and behaviors aimed to channel this perception into 
explicit outcomes (Aknin, Dunn, Whillans, Grant, & Norton, 2013). Thus, high levels of 
perceived impact on beneficiaries has been theorized to result in greater persistence and 
dedication (Grant, 2008), particularly towards those activities through which the action-
result relation becomes more straightforward.  
In our context, we expect that a higher perception of exerting a positive impact on 
patients and clinical practitioners will directly influence the scientists’ engagement in 
actions and outcomes related to improvements on existing therapeutic treatments and 
discovery of new ones.  One of the main tenets of the translational research debate lays 
on the idea that biomedical researchers should be more aware about patients and clinical 
needs (Marincola, 2011). This may lead to the generation of biomedical knowledge and 
research results with a greater potential to be translated into practice. Biomedical 
scientists may conceive their participation in medical innovation as a form to connect 
their research activities to patients and clinical staff needs, and thus may devote greater 
efforts to bridge the gap between basic understanding and healthcare delivery. For 
example, clinical guidelines have emerged as critical tools for improving healthcare 
practices, and represent a tool to strengthen connections between scientists, clinical 
practitioners and patients (Nigam, 2013). We contend that scientists particularly aware of 
the influence they exert on patients through their work will be more likely to embark in 
the identification of opportunities for translational research as well as in the exploitation 
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of such opportunities in various forms, such as in the design of clinical trials or the 
delivery of clinical guidelines. This idea is partially suggested by previous findings from 
the biomedical research community. In 2011, the Federation of American Societies for 
Experimental Biology (FASEB) conducted a survey addressed to basic and clinical 
scientists whose main objective was to explore the benefits for scientists to engage in 
translational research activities. Results from 1,770 collected responses showed that 
nearly three-quarters of the respondents initially decided to participate in translational 
research activities because they were motivated to exert a direct and positive impact on a 
particular disease or condition. Similarly, more than half of the respondents reported that 
they pursued to exert an impact on human health in general through their research 
activities (Hobin et al., 2012). This supports the idea that the greater the scientists’ 
perception of impact on patients and clinical practitioners, the higher their capacity to 
identify and exploit potential opportunities to participate in medical innovation. Thus, we 
propose the following hypothesis:    
Hypothesis 3: Perceived impact on patients and clinical staff will have a positive 
relationship with the scientists’ degree of participation in medical innovation 
activities.  
3 Methods	
3.1 Research	context	
We situate our analysis within the biomedical research field in Spain. In the 
course of the last decade, the Spanish Government has launched a number of public 
policy initiatives and programs aimed to promote translational and cooperative research 
across different biomedical fields. A representative step towards this aim was the creation 
of the Spanish Biomedical Research Networking Centers (henceforth, CIBERs). In 2006, 
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the Spanish Ministry of Health undertook an initiative to reorganize biomedical research 
in Spain as a mean to foster excellence in biomedical research as well as to improve the 
quality, value and effectiveness of the healthcare services delivered to the general 
population. A crucial part of the CIBER program was the development of a formal 
network structure to promote research cooperation among professional groups working 
on similar biomedical research areas, lending greater weigh to hospitals and clinical 
research groups. Thus, applicant biomedical groups could be placed at universities, 
public research organizations, hospitals, clinics and biomedical research foundations in 
Spain. Participant groups were selected through open calls, each call focused on a 
specific range of pathologies or diseases of strategic interest to the Spanish National 
Health System. The acceptance of research groups in the program was subjected to an 
evaluation process based on each groups’ previous research excellence and contributions 
to healthcare. The selected groups were organized around nine biomedical research 
networks, each one related to a particular biomedical research area: Bioengineering, 
Biomaterials and Nanomedicine (CIBER-BBN), Diabetes and Metabolic Associated 
Diseases (CIBER-DEM), Epidemiology and Public Health (CIBER-ESP), Hepatic and 
Digestive Diseases (CIBER-EHD), Obesity and Nutrition (CIBER-OBN), Mental Health 
(CIBER-SAM), Neurodegenerative Diseases (CIBER-NED), Rare Diseases (CIBER-ER) 
and Respiratory Diseases (CIBER-ES).  
3.2 Sample	
The CIBER program provides us with a unique opportunity to study the 
collaborative networks of biomedical scientists, as well as their main individual 
characteristics and their degree of participation in a variety of translational research 
activities and outputs. Our research population comprised all biomedical scientists and 
technicians of every research group belonging to each of the nine CIBER networks. We 
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contacted CIBER’ Scientific Directors to obtain explicit support for our research and 
collected e-mail addresses and complete names of scientists and technicians included in 
all CIBER networks. To develop the survey questionnaire, we conducted a number of 
interviews with Scientific Directors, research groups’ principal investigators and 
biomedical scientists between June 2012 and March 2013. An extensive list of activities 
and outputs related to translational research was obtained from biomedical literature and 
validated through the interview process. The questionnaire was organized in multiple 
sections, with a particular focus on the structure and content of the scientists’ personal 
network. The questionnaire also asked for the involvement of scientists in a range of 
medical innovation activities. Attitudinal and motivational questions were also included 
in the questionnaire, together with a series of questions on respondents’ socio-
demographic aspects, such as age, gender or educational level. In April 2013, the 
questionnaire was distributed to 4,758 biomedical scientists and technicians from all nine 
CIBER networks. In collaboration with the CIBER Scientific Managers, all scientists 
were encouraged to participate in a study aimed to explore the relationship between the 
scientists’ collaboration network, their individual characteristics and their participation in 
medical innovation activities and outputs. 1,309 scientists responded the questionnaire, 
meaning an overall response rate of 27.5%, which is fairly similar to other surveys on 
academic scientists (Perkmann et al., 2013). The distribution of our sample is as follows: 
31,9% of our respondents were affiliated to a University, 35,3% to a hospital, 28,9% to a 
public research institution and 4% were affiliated to private research bodies and other 
similar institutions. Regarding their role in the research group, 10,4% of our respondents 
are principal investigators of their research groups, 53,8% are post-doctoral scientists, 
18,2% are pre-doctoral scientists and 14,2% are technicians or similar positions. 
Response rates across CIBER are fairly evenly distributed (see details in the Appendix). 
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We conducted a number of analyses to test for non-response bias. First, we 
compared response rates in terms of the institutional affiliation, the hierarchical position 
in the research group and the size of the group (archival analysis). Though we found 
significant differences in some aspects, the overall distribution of response rates is fairly 
homogeneous (see Table in the Appendix). Furthermore, we performed a wave analysis 
to check whether responses differ with regards of the date respondents completed the 
questionnaire. This study complements the archival analysis, since the response patterns 
of late respondents may be considered as a proxy for the response patterns of non-
respondents (Rogelberg & Stanton, 2007). Our sample was classified into early 
respondents (45.8%) and late respondents (54.2%). We conducted an ANOVA-analysis 
of the differences in means for the two groups for a sample of actual survey variables 
(participation in medical innovation activities, ego-network size). The hypotheses of 
differences in the means are all rejected, suggesting that our data does not suffer from 
major problems of non-response bias. 
3.3 Variables	
3.3.1 Dependent	 Variable:	 Degree	 of	 participation	 in	 medical	
innovation		
To capture the scientists’ degree of participation in different types of medical 
innovation, we conducted a review of the literature on translational research from the 
most representative biomedical journals. This allowed us to identify a set of 
breakthroughs representing a diversity of outputs and achievements through which 
biomedical knowledge moves forward and backward through different stages of the 
research pipeline. These breakthroughs include the discovery or invention stage, often 
associated with basic research on the root cause of diseases, and generally epitomized by 
the identification of a new molecular target for the discovery of new drugs or diagnostic 
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devices (product discovery). Another breakthrough in the research pipeline is the 
translation of basic findings and discoveries from the lab into specific human clinical 
research, such as clinical trials and observational studies (product development). A 
critical challenge is the transit from new medical compounds or devices into clinical 
practice, for instance, through the development of evidence-based clinical guidelines that 
allow the incorporation of research discoveries into day-to-day clinical practice and 
delivery of healthcare (clinical guidelines). Biomedical scientists have proposed similar 
conceptualizations of the main achievements through the research pipeline (Westfall, 
Mold, & Fagnan, 2007; Dougherty, 2008; Khoury et al., 2007; Sung et al., 2003). While 
dominantly based on a linear approach from ‘the bench to the bedside’, they provide a 
foundation to address the variety of indicators associated to medical innovation.  
We end up with a list of 14 items reflecting this variety of medical innovations, 
which were further validated by biomedical scientists interviewed during the pilot phase 
of the survey. The full list is shown in Table 1 below, as well as a sample of academic 
references supporting the association between each category of items and the delivery of 
medical innovations We asked respondents to report whether they have been engaged in 
each activity, and how often. Specifically, respondents were asked: please indicate how 
frequently you obtained the following research results derived from your research 
activities during the year 2012. They were offered a drop-down menu where they could 
choose any number between 0 to 10 times, or more than 10 times. We conducted a 
principal components analysis (PCA), finding that 11 of our innovation-related outputs 
grouped into 4 factors. Following varimax rotation, results showed that Factor 1 
explained 22% of the total variance in the items, comprising outputs related to invention 
and commercialization (Product generation: invention and commercialization). Factor 2 
accounted for 16% of the variance in the items (drug development). Factor 3 explained 
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13% of variance, grouping outcomes associated with the development of guidelines for 
clinical practitioners and patients (clinical guidelines). Factor 4 accounted for 10% of the 
total variance in the items and groups all items related to the development of diagnostic 
devices and prevention-related activities (Diagnostics and prevention)1.  
Table 1. Grouping medical innovation items into categories. 
Medical Innovation 
Categories (Factors) 
Items  Key references 
Product Generation 
(invention and 
commercialization) 
Patent applications for new drugs 
Licenses granted from patents 
Participation in spin-offs 
(Ding et at., 
2011; Morgan et 
al., 2011) 
New Drug Development   Clinical trials phase I, II or II for new drug 
development 
Clinical trials phase IV for new drug development 
Clinical trials phase IV for new diagnostic 
techniques2 
(Duyk, 2003; 
Khoury et al., 
2007; Westfall, 
et al. , 2007) 
Clinical Guidelines Clinical guidelines for health practitioners 
Clinical guidelines for patients  
(Cochrane et al., 
2007; Dougherty 
& Conway, 
2008) 
Diagnostics and  
prevention  
Patent application for new diagnostic mechanisms 
Clinical trials phase I, II or II for new diagnostic 
mechanisms 
Prevention guidelines for the general population  
(Drolet & 
Lorenzi, 2011; 
Khoury et al, 
2007) 
 
Table 2 shows the rate of scientists that have participated at least once in a 
particular type of medical innovation category, according to the institution they are 
affiliated. The results reported in Table 2 reflect that the most widespread medical 
innovation is the development of clinical guidelines. About 23% of scientists had 
participated in the development of clinical guidelines during the year 2012. Activities 
related to diagnostics and prevention were the least frequent form of medical innovation. 
Only a 10% of scientists have been involved in such type of activities. A deeper analysis 
of the results reflects that there are significant differences in the level of involvement in 
medical innovation categories across respondents’ affiliation. Scientists affiliated to 
                                                 
1 Details of the PCA analysis can be found on Annex 1 
2 We kept this item because factor analysis results indicated a high correlation between this item and the other two items included in 
the category ”new drug development” 
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hospitals and clinics have participated more frequently in all range of medical innovation 
categories, except for the ‘invention and commercialization’ category. 
Table 2: Involvement of scientists in the four medical innovation categories, 
according to institutional affiliation (% of scientists engaged at least once over the 
year 2012 in any of the items included in each of the four medical innovation 
categories).  
 Product 
Generation 
(Invention and 
commercialization) 
New drug 
development 
Clinical 
guideline
s 
Diagnostics 
and prevention 
Total 
cases 
University 19.2 7.5 11.7 8.8 386 
Hospital  12.0 41.4 47.8 12.5 409 
PRO 15.5 8.8 9.4 10.3 341 
Other organizations 15.2 8.8 12.0 7.2 125 
Total 15.5 19.0 22.8 10.2 1261 
We developed an indicator to assess the degree of participation in different forms 
of medical innovation. To do so, we coded scientists from 0 to 3. If scientists reported no 
participation in any of the four categories defined below, we coded 0 (56.3% of our 
sample). If they had engaged at least once in one category, we coded 1 (25.3%). 
Similarly, if they had participated at least once in two of the defined categories, we coded 
2 (14.2%). Finally, if they had participated at least once in three or in all four categories, 
we coded 3 (4.2%). Our dependent variable was further rescaled between 0 and 1, as we 
explain in the section on the econometric results. 
3.3.2 Independent	Variables	
Ego-network brokerage.  We used an ego-centric network approach (e.g.: Baer, 
2010; Smith, Collins, & Clark, 2005) to capture each scientist’ network of critical 
contacts.  Our survey allowed each respondent (ego) to list the names of up to ten 
contacts (alters) from outside their research group whom they considered critical for the 
advancement of their research activities. Specifically, we invited each scientist to “write 
down the names of those persons (up to ten) from outside your research group that are 
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particularly important for the advancement of your research activities”. This question 
was chosen because we were particularly interested in capturing the network of contacts 
that were important for each scientist’ research purposes. In response to this name-
generator question, respondents provided an average number of 3.57 unique contacts 
outside their research group. Then the survey asked respondents for information on each 
alter-alter relationships (Burt, 1992; Podolny & Baron, 1997). Although ego-network 
data is based on individual perceptions, it has been shown that measures from ego-
network data are highly correlated with measures collected from whole-network data 
(Everett & Borgatti, 2005) as well as from data collected from both members of the 
dyadic relationship (Battilana & Casciaro, 2013). Building on previous literature, we 
calculated ego-network brokerage by counting the number of structural holes for each 
ego-network (Everett & Borgatti, 2005). That is, the absence of alter-alter ties between 
each ego-network contact. This sum was then divided by the total number of possible 
alter-alter ties, n (n – 1) / 2. The maximum brokerage score occurs when there are no 
connections between alters in the scientist personal network (ego-network). For each 
individual, this ratio ranged from 0 to 1, with low values reflecting few structural holes 
and high values reflecting many structural holes and therefore, a higher score on ego-
network brokerage. Since the ratio of structural holes is sensitive to ego-network size, we 
controlled for the effect of size in our regression model. 
Breadth of cognitive skills. Our literature review indicated that key barriers to 
the participation of biomedical scientists in medical innovations were directly related to 
the (lack of) specific skills and the highly specialized academic training of scientists 
(Arar & Nandamudi, 2012; Coller, 2008). We identified a pool of biomedical-related 
skills and abilities that were critical for an effective two-way transit between the “bench 
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and the bedside3”. These skills were completed and validated with preliminary interviews 
with biomedical scientists. Finally, we included in the questionnaire a list of nine skills 
and specific abilities: development of clinical trials, clinical guidelines, state of the 
technology, clinical pharmacology, biostatistics, molecular biology; experimental 
methods, animal experimentation and studies with control groups. To elicit how many of 
those skills were possessed by the respondents, the following question was asked: “Have 
you received, through your career, training on one or more of the following activities?”. 
We pointed that this training could have been received in the form of face-to-face 
lectures, on-line courses or any other mode. We operationalized the variable as a direct 
count of the number of different skills indicated by each respondent.  
Perceived impact on beneficiaries. To capture the perceived impact of scientists’ 
research results into social agents from a clinical context, we used a seven-point Likert 
scale adapted from the beneficiary impact scale proposed by Grant (2008). Since all our 
respondents were involved in biomedical research, we explicitly consider the perceived 
impact of their research activities on three different groups: patients, clinical practitioners 
and vulnerable social groups. Specifically, our question asked: “Please, indicate the 
extent to which the following collectivities benefit more directly from the results obtained 
from your research activities”. We averaged the responses to the three items to create a 
composite indicator of the perceived clinical impact of the research activities 
(Cronbach’s Alpha = 0, 78). 
Control variables. Several factors that are outside the scope of our hypotheses 
could influence the respondents’ degree of participation in medical innovation. We 
controlled for these factors in the statistical analysis. We accounted for control variables 
                                                 
3 Journals considered for the literature review include: Journal of the American Medical Association 
(JAMA), Nature Medicine, Translational Research, Journal of Translational Medicine, British Medical 
Journal and Clinical and Translational Science (among others).    
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at the individual level and at the research group level. To control for the effect of 
accumulated learning and experience in the propensity to engage in TR activities, we 
controlled for the age of the respondents (Age).  Similarly, we also used a dummy 
variable to account for those respondents who have a PhD, taking value of 1 if the 
respondent reported to have a PhD degree, zero otherwise (PhD). Given that the number 
of contacts may affect the number of structural holes to which each respondent can 
access we effectively controlled for the size of each scientist’ ego-network. We included 
a dummy variable which was coded 1 for those respondents having a large ego-network 
(more than 4 contacts reported by the respondent). Selecting this threshold allowed us to 
capture the top 30% of our respondents having larger personal networks. Respondents 
with 4 or less contacts were coded 0 (Ego-network external size).  In addition, we defined 
nine dummy variables to control for the scientific field of each respondent, leaving 
CIBER-BBN as the default group. Depending on the type of institution where each 
respondent belongs there may be few or many opportunities to engage in medical 
innovation activities. Accordingly, we controlled for that by including 4 dummies 
reflecting the type of institution of the respondent. Specifically, the type of institution can 
be university, hospital/clinic, public research organization and other type of institution 
(the latter being the reference category in the econometric analysis). Finally, we resorted 
to the CIBERs’ scientific reports to retrieve information about the number of scientists 
working in each research group (Group size). 
4 Results	
4.1 Descriptive	analyses	and	correlations	
Table 3 provides the descriptive statistics and correlations for the variables used 
in the model.  The average ego-network brokerage score was 0.63 (SD=0.33). For the 
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purpose of this study, we are particularly interested in the heterogeneity of the 
respondents’ ego-network structure. The histogram displayed below (Figure 1) shows 
that biomedical scientists’ exhibit significant variability in terms of their ego-network 
structure, reflected as their brokerage scores. We observe that the proportion of cases at 
the extremes of the score-range distribution is particularly high. The high frequency of 
1’s indicates that, for a significant proportion of scientists, none of the egos’ contacts are 
connected among them, while the high number of 0’s corresponds to those egos whose 
contacts are all connected among them. 
Figure 1: Histogram of ego-network brokerage scores 
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Table 3: Descriptives and Correlations 
 Variable Mean s.d. Min Max 1 2 3 4 5 6 7 8 9 10 11 
1. Engagement in Medical Innovation 0.221 0.290 0.000 1.000 1.000           
2. Ego-network brokerage 0.634 0.333 0.000 1.000 -0.010 1.000          
3. Cognitive breadth 2.711 1.882 0.000 9.000 0.213*** 0.002 1.000         
4. Perceived beneficiaries 4.437 1.455 1.000 7.000 0.266*** -0.111** 0.181*** 1.000        
5. Large ego-networka 0.310 0.463 0.000 1.000 0.124*** 0.185*** 0.155*** 0.108*** 1.000       
6. Age 41.894 10.651 23.000 78.000 0.282*** 0.054 0.096 0.062* 0.129*** 1.000      
7. PhDa 0.628 0.484 0.000 1.000 0.134*** 0.058† 0.192*** -0.010 0.137*** 0.410*** 1.000     
8. Group size 18.248 10.457 2.000 79.000 -0.038 -0.042 -0.131*** -0.031 -0.031 -0.193*** -0.096** 1.000    
9. Universitya 0.306 0.461 0.000 1.000 -0.151*** 0.036 -0.109*** -0.150*** 0.005 -0.039 0.076† 0.135*** 1.000   
10. Hospitala 0.324 0.468 0.000 1.000 0.362*** -0.042 0.187*** 0.232*** 0.038 0.188*** 0.032 -0.055† -0.460*** 1.000  
11. Public Research Organizationa 0.270 0.444 0.000 1.000 -0.165*** 0.013 -0.050† -0.100*** -0.067* -0.112*** -0.089* -0.077** -0.404*** -0.422*** 1.000 
†10% (p<0.10); *5% (p<0.05); **1% (p<0.01); ***0.1% (p<0.001). 
a Dummy variables 
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Illustrating the ego-networks of two scientists from our sample is useful to 
visualize how their personal network structures differ and, therefore, how different are 
the potential sources of information they can tap into when facing a research problem. To 
do so, we selected two respondents from the same CIBER network (CIBER-NED: 
neurodegenerative diseases) and with the same external network size (six alters). Despite 
the identical size of their external networks, , they exhibit a significant difference in their 
brokerage score. The scientist on the left side (Ego 1) reported that only two of the 
mentioned alters (alters 1 and 6) were connected among them, while all other alters do 
not known each other. That implies that the only connection between alters is provided 
through their mutual relations with the ego. As outlined above, disconnected contacts are 
more likely to operate with different ideas and practices. It is this broader exposure to 
variation that provides the ego an opportunity to develop different ways of looking at 
medical problems and access to a diverse range of resources and knowledge. The ego-
network brokerage score for this respondent is comparatively high: 0.933 (one reported 
connection among alters, over fifteen possible). In contrast, the second scientist reported 
to have a much more densely connected network. The closure benefits of ego-networks 
are related to more efficient coordination of alters as trust is more easily elicited in this 
case. However, it is likely that much of the information and resources accessible through 
these contacts will be redundant, since it will be much more homogeneous compared to 
the previous case. In this case, the brokerage score is comparatively low: 0.267 (eleven 
reported connections among alters, over fifteen possible). 
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Figure 2: Graphical representation of two ego-network structures 
 Ego 1 Ego 2 
   
4.2 Econometric	analysis	and	results	
Given that our dependent variable takes non-negative integer values (ranging 
between 0 and 3), standard regression techniques, such as OLS, are not fully appropriate 
for modelling this type of variables. To accommodate the bounded nature of our 
dependent variable, we conduct a Fractional Logit regression by rescaling the original 
scores within the range between 0 and 1.4 Fractional Logit regressions are particularly 
suitable for dependent variables that are bounded (such as proportions and percentages) 
or for constructed variables crafted to take values within a specified range (such as Likert 
scales) (Fossett et al., 2012). The results of the Fractional Logit regression are reported in 
Table 4, together with OLS results that serve as a point of reference. In both cases, we 
provide the results for three Models. Models 1 and 2 include our full sample. However, 
as some of the researchers reported having zero or only 1 relevant contact, they cannot 
play any type of brokerage role by definition. In these cases, recognizing that the absence 
                                                 
4 We rescale the scores of the original variable Yi into a proportion Pi, such as: Pi = (Yi – Ymin) / (Ymax – 
Ymin), where Ymin e Ymax are the extreme values of the original variable Yi . 
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of contacts is qualitatively different from a zero score for brokerage, we have included a 
dummy variable (i.e. Dummy Ext. Contacts < 2), to indicate that a score of zero for this 
individuals reflects having less than two critical external contacts. While Model 1 
includes only the control variables, Model 2 shows the results for the full model. Our 
Model 3 is the one including only those researchers (i.e. 853 observations) who report at 
least two critical external contacts. 
In Hypothesis 1 we predicted a quadratic (inverted U-shaped) relationship 
between the ego-network brokerage score and the involvement in medical innovation. 
The coefficient for the ego-network brokerage is positive and significant, while the 
coefficient for the ego-network brokerage squared is negative and significant, in our full 
models. Figure 3 shows the quadratic association between ego-network brokerage score 
and the degree of participation in medical innovation. The shape of the relationship is 
consistent with the hypothesis. Thus, Hypothesis 1 was supported.  
Hypothesis 2 predicted that the breadth of cognitive skills was positively 
associated to the involvement in medical innovation. The coefficient is always positive 
and significant, which provides support for hypothesis 2. Hypothesis 3, which proposed 
that scientists’ perceived impact on patients and clinical practitioners would be positively 
related to their involvement in medical innovation, was also supported. The coefficient is 
positive and significant in all our specifications.  
Among the control variables, we found that scientists working at hospital settings 
are more likely to participate in medical innovation. Further, we found that age also 
predicts the engagement in medical innovation. 
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Figure 3: Ego-network brokerage and engagement in medical innovation 
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Table 4. Results for Fractional Logit and OLS Regression Analyses 
 Fractional Logit OLS 
 Model 1  Model 2 Model 3 Model 1 Model 2 Model 3 
Predictor variables       
Ego-net. brokerage --- 1.604** 1.721** --- 0.247** 0.249** 
  (0.739) (0.704)  (0.101) (0.104) 
Ego-net. brokerage2 --- -1.259* -1.320** --- -0.220** -0.217** 
  (0.694) (0.661)  (0.094) (0.098) 
Cognitive breadth --- 0.114*** 0.125*** --- 0.018*** 0.021*** 
  (0.033) (0.036)  (0.005) (0.005) 
Perceived benefic. --- 0.289*** 0.323*** --- 0.034*** 0.039*** 
  (0.041) (0.048)  (0.006) (0.007) 
Control variables       
Age 0.033*** 0.034*** 0.036*** 0.005*** 0.005*** 0.005*** 
 (0.006) (0.006) (0.006) (0.001) (0.001) (0.001) 
Large ego-network 0.258** -0.023 -0.043 0.040** 0.001 -0.003 
 (0.126) (0.145) (0.139) (0.182) (0.019) (0.020) 
PhD 0.157 0.190 0.015 0.020 0.018 0.004 
 (0.126) (0.132) (0.155) (0.018) (0.018) (0.022) 
Group size 0.005 0.008 0.011* 0.001 0.001 0.002* 
 (0.006) (0.006) (0.007) (0.001) (0.001) (0.001) 
University 0.057 0.050 -0.155 -0.001 0.010 -0.005 
 (0.197) (0.206) (0.223) (0.028) (0.028) (0.033) 
Hospital 1.150*** 0.982*** 0.924*** 0.189*** 0.169*** 0.168*** 
 (0.202) (0.211) (0.228) (0.029) (0.029) (0.034) 
Public Res. Org. 0.124 0.082 0.051 0.018 0.025 0.024 
 (0.200) (0.209) (0.229) (0.029) (0.028) (0.034) 
Dummy Ext. Contacts (< 2) -0.273** 0.111 --- -0.028 0.014 --- 
 (0.135) (0.195)  (0.019) (0.027)  
Constant -3.330*** -5.168*** -5.029*** -0.082** -0.294*** -0.310*** 
 (0.314) (0.399) (0.438) (0.045) (0.054) (0.065) 
Dummy CIBERs  (8 dummies) Included Included Included Included Included Included 
      Adjusted - R2 (1) 0.193 0.235 0.230 0.182 0.226 0.219 
      Observations 1157 1157 853 1157 1157 853 
* p < 0.1, ** p < 0.05, *** p 0.01 
(1). For OLS, we report Adjusted R2. For Fractional Logit, our R2 is the square of the correlation between predicted and original values of our dependent variable. 
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5 Conclusions	and	implications	
Our study aimed to theoretically and empirically analyze the medical scientists’ 
personal network structures and individual attributes that are particularly conducive to 
their participation in a range of medical innovation activities. The majority of the 
discussion around the relevance of translational research and innovation in healthcare has 
emphasized the importance of promoting collaborative links between biomedical agents 
belonging to different communities of practice, but much less has been discussed around 
the potential costs associated with the development and maintenance of brokerage 
positions. Combined with the fact that medical scientists also differ in their capacity and 
willingness to establish effective research networks, this suggest room to a deeper 
analysis on the consequences of occupying brokerage positions in the medical context.   .  
Thus, this study elucidates the theoretical link between ego-network structure and 
participation in medical innovation activities. It investigates what types of personal 
networks are most conducive to innovation in biomedicine. While existing social capital 
research generally recognizes that innovation is a socially embedded endeavor, 
significant gaps remain in understanding whether there is an optimum level of personal 
network brokerage in which scientists’ engagement in medical innovation is maximized. 
Our results show that there is an inverted U-shape relationship between scientists’ ego-
network brokerage scores and their participation in innovation. We see this as a reflection 
of the theorized trade-off between sparse and dense personal networks. On the one hand, 
results support the logic that the information and control advantages associated with 
brokerage positions (Burt, 1995, 2004) operate to facilitate scientists’ participation in 
various forms of medical innovation activities. From a normative perspective, our results 
suggest that scientist devoting more time and efforts in cultivating and maintaining a 
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sparse network of contacts and interactions outside their formal research group would be 
in an advantageous position to deliver higher levels of medical innovation. On the other 
hand, our data confirmed that potential brokerage benefits do not come without a cost. 
Beyond a threshold,  costs of building and maintaining a sparse network may surpass its 
potential benefits and ultimately be detrimental for the scientists’ participation in medical 
innovation activities. These costs might be reflected in the form of higher coordination 
needs or a decreasing trust among network members, which may difficult the flow of 
knowledge around the network or cognitive costs related to the utilization of disparate 
pockets of knowledge. Further, actors connecting disparate others are subjected to 
different sets of role expectations, which may be sometimes in conflict (Soda & Zaheer, 
2012). Therefore, our results show that both facets of brokerage’s potential actually 
operate in the medical context, indicating that the most effective  personal network 
structure lays at an intermediate level between a dense network (where most of the 
contacts know each other) and a sparse network (where most of the contacts do not 
known each other).  
This study also identifies two individual-level variables that exert a significant 
impact on the participation in medical innovation, namely cognitive breadth and 
perceived beneficiary impact. We presented a pool of skills associated with basic 
biomedical and clinical research. Those scientists who reported to have a wider 
knowledge about the proposed skills were more likely to participate in innovation. This 
suggests the need to formalize and promote translational research studies and courses as a 
way to facilitate communication and integration between biomedical agents. These 
findings provide empirical evidence to recent claims from the biomedical community 
(e.g.: Kurpinski et al., 2014; Rubio et al., 2010), which have suggested that bridging the 
gap from lab bench to patient bedside requires a unique set of skills that are not typically 
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offered by traditional degree programs.  Finally, we found that scientists that are 
particularly aware of the positive impact they exert over patients and clinical 
practitioners are more prone to engage in different forms of medical innovation. These 
results seem to be aligned with previous findings reported in organizational behavior and 
social psychology literature, which have highlighted that when individuals perceive that 
their actions have an impact on beneficiaries, they are likely to engage in the pursuit of 
making a positive difference in these beneficiaries’ lives (Grant, 2007). Our results 
indicate that biomedical scientists may conceive the engagement in innovation activities 
as a way to channel such interest. Therefore, this suggests that developing and 
implementing mechanisms to increase the scientists’ awareness of their direct impact on 
patients and clinical staff might enable scientists to participate more frequently in 
medical innovation activities.   
To sum up, our use of the social capital discussion between dense and sparse 
networks is valuable in addressing the increasing interest among the medical community 
on the importance of knowledge brokers. Through this analysis, we have proposed a 
personal network perspective to examine the mechanisms through which different 
network structures may lead to different levels of medical innovation, and we offered a 
theoretical framework to deeply explore the interactions between different actors in the 
biomedical context. By adopting an individual perspective, we also bring onto our study 
two potential individual-level antecedents to explain differences in medical innovation 
engagement: cognitive breadth and perceived beneficiary impact. 
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Appendix	
Table: Response rate by CIBER  
 Population surveyed
Nº of completed 
returned 
questionnaires 
Response rate (%) 
CIBER – BBN 872 238 27.3 
CIBER – DEM 331 96 29.0 
CIBER – EHD 459 154 33.6* 
CIBER – ER 517 177 34.2* 
CIBER – ES 439 159 36.2* 
CIBER – ESP 610 107 17.5* 
CIBER – NED 750 186 24.8 
CIBER – OBN 303 71 23.4 
CIBER – SAM 477 121 25.4 
Total 4758 1309 27.5 
Note: * indicates significant statistical difference in response rates (p < 0.05). Statistical 
significance was calculated by comparing the relative frequency with which the surveyed 
scientists are classified into the categories of non-respondents and respondents (using a Chi-
square test). 
